
Adult Immunization
about 2 months ago
JN.1 COVID-19 Booster Safety Confirmed in Large Study: Daily Doseabout 2 months ago
Vaccine Policy Shifts, Public Trust, and Countering MisinformationLatest News

Obesity Still Plagues the US, But Rates Are Declining in Some States: The Trust for America's Health Report

Multidisciplinary Lung Cancer Screening Program Achieves Screening Rates Above 70%

The Menopause Society 2025 Annual Meeting: A Primary Care Preview

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose

Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials

Shorts










Latest Videos
Podcasts
Screening
All News

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

Your daily dose of the clinical news you may have missed.

A large Australian study found that training primary care physicians increased long-term LARC use, reduced unintended pregnancies, and improved reproductive health outcomes.

An 18-year multicohort study found that smokers who quit even in later life showed 20% slower memory decline vs those who continued to smoke.

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

Your daily dose of the clinical news you may have missed.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.